Christopher Burston’s bowel cancer appeared to disappear after just nine weeks of immunotherapy, yet he still underwent surgery. The British patient, diagnosed with stage III bowel cancer in 2023, participated in a clinical trial involving 32 patients, with researchers reporting no cancer relapses during nearly three years of follow-up. The findings, which gained renewed attention in October 2026, suggest a promising approach to treating certain colorectal cancers. But Burston’s experience raise